Various PKC modulators with promising anticancer activity as single agents have been tested to reverse resistance to cytotoxic chemotherapy, providing a rationale for the development of drug combinations with PKC modulators in a number of human tumours. The gene discussed is PRRT2; the disease is neoplasm.